Elias Jabbour, MD, talks about obe-cel ASH updates, FDA approval

Dr. Jabbour discusses obecabtagene autoleucel (obe-cel), an autologous CD19-directed chimeric antigen receptor (CAR)-T cell therapy, in relapsed or refractory adult B-cell acute lymphoblastic leukemia during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.

Dr. Jabbour presented an ASH abstract titled, “Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): deep molecular remission may predict better outcomes.”